BioRestorative Therapies Inc (BRTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $2.06M
Last updated: Nov 17, 2026 at 11:00 AM ET
BioRestorative Therapies Inc (BRTX) Earnings: Report Dates and Results
BioRestorative Therapies (BRTX) is expected to report earnings on Mar 24, 2027. In the quarter ended Sep 30, 2026, BioRestorative Therapies reported EPS of -$7.60, below the -$2.60 estimate. It beat the EPS estimate in 6 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
BRTX has an expected report date of Mar 24, 2027.
BRTX Earnings Call
The latest BRTX earnings call transcript on file is labeled 2025Q3.
Read the 2025Q3 transcriptEarnings History
Of the 20 quarters below that had an estimate, BRTX beat 13, missed 6 and matched 1. The widest gap in the table came in the quarter ended Sep 30, 2026, when EPS landed 192.31% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$7.60 | -$2.60 | -$2.60 - -$2.60 | -192.31% | Miss | N/A | 1 | 1 up, 0 down | Nov 11, 2026 | N/A |
| Jun 30, 2026 | $6.00 | $3.00 | N/A | +100.00% | Beat | N/A | 1 | 1 up, 0 down | Aug 31, 2026 | N/A |
| Mar 31, 2026 | -$0.12 | -$0.30 | -$0.30 - -$0.30 | +60.00% | Beat | N/A | 1 | 1 up, 0 down | May 14, 2026 | $23170 |
| Dec 31, 2025 | -$0.32 | -$0.34 | N/A | +5.88% | Beat | N/A | 1 | 0 up, 1 down | Mar 26, 2026 | $19600 |
| Sep 30, 2025 | -$0.33 | -$0.38 | -$0.38 - -$0.38 | +13.16% | Beat | N/A | 1 | 0 up, 1 down | Nov 12, 2025 | $11800 |
| Jun 30, 2025 | -$0.30 | -$0.41 | -$0.41 - -$0.41 | +26.83% | Beat | N/A | 1 | 0 up, 1 down | Aug 12, 2025 | $303300 |
| Mar 31, 2025 | -$0.64 | -$0.32 | -$0.32 - -$0.32 | -100.00% | Miss | N/A | 1 | 0 up, 1 down | May 14, 2025 | $25000 |
| Dec 31, 2024 | -$0.38 | -$0.55 | N/A | +32.22% | Beat | N/A | 1 | 0 up, 1 down | Mar 27, 2025 | $43300 |
| Sep 30, 2024 | -$0.01 | -$0.35 | -$0.51 - -$0.35 | +97.14% | Beat | N/A | 2 | 1 up, 0 down | Nov 12, 2024 | $233600 |
| Jun 30, 2024 | -$0.28 | -$0.56 | -$0.56 - -$0.56 | +50.00% | Beat | N/A | 1 | 0 up, 0 down | Aug 13, 2024 | $89100 |
| Mar 31, 2024 | -$0.59 | -$0.51 | -$0.53 - -$0.51 | -15.69% | Miss | N/A | 2 | 0 up, 0 down | Jun 11, 2024 | $35000 |
| Dec 31, 2023 | -$0.57 | -$0.69 | -$0.73 - -$0.65 | +17.39% | Beat | N/A | 2 | 0 up, 0 down | Mar 29, 2024 | $19300 |
| Sep 30, 2023 | -$0.64 | -$0.68 | -$0.68 - -$0.68 | +5.88% | Beat | N/A | 1 | 0 up, 0 down | Nov 13, 2023 | $30700 |
| Jun 30, 2023 | -$0.77 | -$1.56 | -$1.56 - -$0.82 | +50.64% | Beat | N/A | 2 | 0 up, 0 down | Aug 11, 2023 | $64500 |
| Mar 31, 2023 | -$1.53 | -$1.26 | -$1.26 - -$1.26 | -21.43% | Miss | N/A | 1 | 1 up, 0 down | May 12, 2023 | $31300 |
| Dec 31, 2022 | -$1.18 | -$1.35 | -$1.56 - -$1.30 | +12.59% | Beat | N/A | 2 | 0 up, 0 down | Mar 24, 2023 | $3700 |
| Sep 30, 2022 | -$1.28 | -$1.45 | -$1.45 - -$1.45 | +11.72% | Beat | N/A | 1 | 0 up, 0 down | Nov 14, 2022 | $29000 |
| Jun 30, 2022 | -$1.28 | -$0.55 | -$0.55 - -$0.55 | -132.73% | Miss | N/A | 1 | 0 up, 0 down | Aug 15, 2022 | $71100 |
| Mar 31, 2022 | -$1.37 | -$0.63 | -$0.63 - -$0.63 | -117.46% | Miss | N/A | 1 | 0 up, 0 down | May 16, 2022 | $16000 |
| Dec 31, 2021 | -$6.90 | -$0.54 | -$0.54 - -$0.54 | N/A | N/A | N/A | 1 | 0 up, 0 down | Mar 30, 2022 | $5000 |
| Sep 30, 2021 | -$4.99 | -$4.99 | N/A | 0.00% | In line | N/A | N/A | N/A | Nov 15, 2021 | $8000 |
| Jun 30, 2021 | -$5.10 | N/A | N/A | N/A | N/A | -103.5% | N/A | N/A | Aug 16, 2021 | $15000 |
| Mar 31, 2021 | -$0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 17, 2021 | $18000 |
| Dec 31, 2020 | -$0.04 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 29, 2021 | $17000 |
| Sep 30, 2020 | -$41.95 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Sep 30, 2020 | $15000 |
| Jun 30, 2020 | $144.27 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 30, 2020 | $19000 |
| Mar 31, 2020 | -$629.18 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 29, 2020 | $26000 |
| Dec 31, 2019 | -$0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 30, 2020 | $32000 |
| Sep 30, 2019 | -$0.23 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 13, 2019 | $38000 |
| Jun 30, 2019 | -$0.24 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 14, 2019 | $31000 |
| Mar 31, 2019 | -$0.28 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 14, 2019 | $29000 |
| Dec 31, 2018 | -$0.35 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 29, 2019 | $29000 |
| Sep 30, 2018 | -$0.39 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 13, 2018 | $26000 |
| Jun 30, 2018 | -$0.53 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 14, 2018 | $37000 |
| Mar 31, 2018 | -$0.33 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Apr 2, 2018 | $19000 |
| Dec 31, 2017 | -$0.39 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 31, 2018 | $38000 |
| Sep 30, 2017 | -$0.37 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 14, 2017 | $16000 |
| Jun 30, 2017 | -$0.37 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 14, 2017 | $20000 |
| Mar 31, 2017 | -$0.51 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 15, 2017 | $7000 |
| Dec 31, 2016 | -$0.56 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 21, 2017 | $6075 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$1.59, after -$1.26 the year before. It was -$2.00 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$1.59 | N/A |
| Dec 31, 2024 | -$1.26 | N/A |
| Dec 31, 2023 | -$3.51 | N/A |
| Dec 31, 2022 | -$5.11 | N/A |
| Dec 31, 2021 | -$17.00 | N/A |
| Dec 31, 2020 | -$526.91 | N/A |
| Dec 31, 2019 | -$0.76 | N/A |
| Dec 31, 2018 | -$1.60 | N/A |
| Dec 31, 2017 | -$1.64 | N/A |
| Dec 31, 2016 | -$2.00 | N/A |
Earnings Calls
The 5 most recent earnings calls are listed below; the latest, 2025Q3 for the period ended Sep 30, 2025, runs about 4,100 words across 7 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2025Q3 | Sep 30, 2025 | 4,146 | 7 | |
| 2025Q2 | Jun 30, 2025 | 2,869 | 7 | |
| 2025Q1 | Mar 31, 2025 | 3,265 | 7 | |
| 2024Q3 | Sep 30, 2024 | 3,973 | 7 | |
| 2024Q2 | Jun 30, 2024 | 4,363 | 9 |
2025Q3 Earnings Call
Opening remarks
Stephen Kilmer Investor Relations Thank you. Good afternoon, everyone. Let me start by pointing out that this conference call will include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are based on BioRestorative Therapies' current beliefs, assumptions, and expectations. Such statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to be materially different from those implied by such statements. No forward-looking statement can be guaranteed. For details on factors, among others, that could affect expectations, see Part 1, Item 1A of our annual report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission. Listeners are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this conference call. BioRestorative Therapies undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, other than as required by law. On the call today, representing the company are Lance Alstodt, BioRestorative Therapies' President, Chairman, and Chief Executive Officer; Francisco J. Silva, Vice President of Research and Development; and Robert Eugene Kristal, the company's Chief Financial Officer. With that said, I'll now turn the call over to Lance.
Lance Alstodt CEO Thanks, Stephen, and good afternoon, everyone. Welcome. On behalf of the management team and everyone at BioRestorative Therapies, I would like to thank you for your interest in our company. For those of you who are shareholders, we appreciate your continued support. As you can see from the press release we issued just a short time ago, we continue to execute well across all areas of our business in the third quarter. We have a lot of exciting things to look forward to as we move through the last couple of months of the year. With that said, I'd like to ask Robert Eugene Kristal, our CFO, to provide a brief overview of our third-quarter financial results.
Robert Eugene Kristal CFO Thanks, Lance. Good afternoon, everyone. To streamline the presentation of the financial results, all the numbers I will refer to have been rounded, so they are approximate. Third-quarter 2025 revenues were $11,800 and consisted entirely of royalty revenue. This compares to revenues of $233,600 in Q3 2024, the vast majority of which came from biocosmeceutical sales in connection with our exclusive supply agreement with Cartessa. The overall year-over-year decrease in Q3 2025 revenues was driven by the timing of orders for the developing biocosmeceutical revenue stream. The company's third-quarter 2025 loss from operations was $3.7 million compared to $2.3 million for the comparable period of 2024.
Frequently Asked Questions About BRTX
When is BioRestorative Therapies's next earnings date?
BioRestorative Therapies's next earnings report is expected for Mar 24, 2027.
Did BRTX beat earnings estimates last quarter?
No. BioRestorative Therapies reported EPS of -$7.60 for the quarter ended Sep 30, 2026, below the -$2.60 estimate by 192.31%.
What EPS do analysts expect from BRTX next quarter?
The consensus EPS estimate for BioRestorative Therapies for the quarter ending Dec 31, 2026 is -$2.04 from 4 analysts, with estimates from -$2.55 to -$1.47.
How often does BRTX beat earnings estimates?
BioRestorative Therapies beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of -6.78%.
BRTX pages: Overview, Earnings, Forecast, Financials, Competitors